XML 64 R54.htm IDEA: XBRL DOCUMENT
v3.5.0.2

Development and License Agreements - Additional Information (Detail) € in Millions | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | ---
Jun. 30, 2016 USD ($) | Jun. 30, 2016 USD ($) | Jun. 30, 2015 USD ($) | Jun. 30, 2016 USD ($) | Jun. 30, 2016 EUR (€) | Jun. 30, 2015 USD ($) | Dec. 31, 2016 EUR (€) | Jun. 30, 2016 EUR (€) | Dec. 31, 2015 USD ($) | Dec. 31, 2015 EUR (€)
Licenses Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Manufacturing and development obligations - current | $ 2,221,000 | $ 2,221,000 |  | $ 2,221,000 |  |  |  |  | $ 3,282,000 |
Manufacturing and development obligations - non-current | 4,844,000 | 4,844,000 |  | 4,844,000 |  |  |  |  | 4,542,000 |
Payments made relating to the manufacturing of the products |  | 3,500,000 | $ 4,700,000 | 7,000,000 |  | $ 9,400,000 |  |  |  |
Amounts due from Fresenius | $ 900,000 | 900,000 |  | 900,000 |  |  |  |  | 200,000 |
BARDA Agreement |  |  |  |  |  |  |  |  |  |
Licenses Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Period of agreement | 5 years |  |  |  |  |  |  |  |  |
Contracts revenue |  | 0 | $ 0 | 0 |  | $ 0 |  |  |  |
BARDA Agreement | Maximum | Base Period |  |  |  |  |  |  |  |  |  |
Licenses Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Committed fund receivable | $ 30,800,000 | 30,800,000 |  | 30,800,000 |  |  |  |  |  |
BARDA Agreement | Maximum | Option Period |  |  |  |  |  |  |  |  |  |
Licenses Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Committed fund receivable | 180,500,000 | 180,500,000 |  | 180,500,000 |  |  |  |  |  |
Other current assets |  |  |  |  |  |  |  |  |  |
Licenses Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Research and development assets | 3,300,000 | 3,300,000 |  | 3,300,000 |  |  |  |  | 4,100,000 |
Other assets |  |  |  |  |  |  |  |  |  |
Licenses Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Manufacturing efficiency assets | 2,200,000 | 2,200,000 |  | 2,200,000 |  |  |  |  | 2,400,000 |
Fresenius |  |  |  |  |  |  |  |  |  |
Licenses Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Allocated amount for research and development activities | 4,800,000 | 4,800,000 |  | 4,800,000 |  |  |  |  |  |
Manufacturing efficiency activity cost | 2,400,000 | 2,400,000 |  | 2,400,000 |  |  |  |  |  |
Cerus Corporation | BARDA Agreement |  |  |  |  |  |  |  |  |  |
Licenses Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Co-investment by the company |  |  |  | 14,500,000 |  |  |  |  |  |
Manufacturing and Supply Agreement |  |  |  |  |  |  |  |  |  |
Licenses Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Accrual for manufacturing of entity products | 2,800,000 | 2,800,000 |  | 2,800,000 |  |  |  |  | 2,500,000 |
Manufacturing and Supply Agreement | Fresenius |  |  |  |  |  |  |  |  |  |
Licenses Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Accrual for manufacturing and development of entity products | 7,000,000 | 7,000,000 |  | $ 7,000,000 |  |  |  | € 6.4 | 7,800,000 | € 7.2
Manufacturing and development obligations, discount rate |  |  |  | 9.72% | 9.72% |  |  |  |  |
Manufacturing and development obligations - current | 2,200,000 | 2,200,000 |  | $ 2,200,000 |  |  |  | 2.0 | 3,300,000 | 3.0
Manufacturing and development obligations - non-current | $ 4,800,000 | $ 4,800,000 |  | 4,800,000 |  |  |  | € 4.4 | $ 4,500,000 | € 4.2
Manufacturing and development payments |  |  |  | $ 1,200,000 | € 1.1 |  |  |  |  |
Scenario Forecast | Manufacturing and Supply Agreement | Fresenius |  |  |  |  |  |  |  |  |  |
Licenses Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Payments made based on the successful achievement of production volumes | € |  |  |  |  |  |  | € 8.6 |  |  |

X
- Definition Accrual For Manufacturing And Development Payment Liability + References No definition available. + Details
Name: | cers_AccrualForManufacturingAndDevelopmentPaymentLiability
Namespace Prefix: | cers_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Accrual for Manufacturing and Development Payment Liability, Current + References No definition available. + Details
Name: | cers_AccrualForManufacturingAndDevelopmentPaymentLiabilityCurrent
Namespace Prefix: | cers_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Accrual for Manufacturing and Development Payment Liability, Noncurrent + References No definition available. + Details
Name: | cers_AccrualForManufacturingAndDevelopmentPaymentLiabilityNoncurrent
Namespace Prefix: | cers_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Accrual for Manufacturing of Entity Products + References No definition available. + Details
Name: | cers_AccrualForManufacturingOfEntityProducts
Namespace Prefix: | cers_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Base period maximum funding of collaborative agreement. + References No definition available. + Details
Name: | cers_BasePeriodMaximumFundingOfCollaborativeAgreement
Namespace Prefix: | cers_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Co-investment for collaborative agreement. + References No definition available. + Details
Name: | cers_CoInvestmentForCollaborativeAgreement
Namespace Prefix: | cers_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Licenses Agreements [Line Items] + References No definition available. + Details
Name: | cers_LicensesAgreementsLineItems
Namespace Prefix: | cers_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Manufacturing And Development Payment Liability + References No definition available. + Details
Name: | cers_ManufacturingAndDevelopmentPaymentLiability
Namespace Prefix: | cers_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Manufacturing Efficiency Assets + References No definition available. + Details
Name: | cers_ManufacturingEfficiencyAssets
Namespace Prefix: | cers_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Option period maximum funding of collaborative agreement. + References No definition available. + Details
Name: | cers_OptionPeriodMaximumFundingOfCollaborativeAgreement
Namespace Prefix: | cers_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Payment for manufacturing of entity products. + References No definition available. + Details
Name: | cers_PaymentForManufacturingOfEntityProducts
Namespace Prefix: | cers_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payment Liability Allocated To Development Activities + References No definition available. + Details
Name: | cers_PaymentLiabilityAllocatedToDevelopmentActivities
Namespace Prefix: | cers_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Payment Liability Allocated To Manufacturing Activities + References No definition available. + Details
Name: | cers_PaymentLiabilityAllocatedToManufacturingActivities
Namespace Prefix: | cers_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Payments For Manufacturing And Development Cost + References No definition available. + Details
Name: | cers_PaymentsForManufacturingAndDevelopmentCost
Namespace Prefix: | cers_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Term of collaborative agreement. + References No definition available. + Details
Name: | cers_TermOfCollaborativeAgreement
Namespace Prefix: | cers_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Unamortized Deferred Cost For Development Activities + References No definition available. + Details
Name: | cers_UnamortizedDeferredCostForDevelopmentActivities
Namespace Prefix: | cers_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Carrying amount as of the balance sheet date, net of allowance for doubtful accounts, of account and note receivables due from other than related parties. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3-4) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_AccountsAndNotesReceivableNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_ContractsRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb) -URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueInputsDiscountRate
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cers_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=cers_BasePeriodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=cers_OptionPeriodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=cers_FreseniusKabiAGMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=cers_CerusCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cers_ManufacturingAndSupplyAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |